A Y Combinator W25 startup (Austin, founded by Josh Sabol, formerly an AWS product manager) that pre-screens patients for clinical trial eligibility by connecting directly to site EHR systems and translating trial inclusion/exclusion criteria into executable logic. It scans full patient records, including scanned documents and faxed PDFs, and returns candidate lists with evidence citations for coordinators or physicians to review. Integration covers Athena, Veradigm Allscripts, Epic, NextGen, MedConnect, Practice Fusion, and eClinicalWorks, with the vendor stating that any certified EHR integrates at no cost. Pricing is a success fee with $0 upfront—the vendor says it charges only when a qualifying patient is successfully identified—and a promotional period running to July 31, 2026 waives a $15,000 implementation fee, $5,000 trial setup fee, and $2,500 premium support fee. Published case figures include Alnylam’s ZENITH trial (4,269 patients, 364,607 records, 24 criteria, roughly 1,280 hours of manual review saved), Eli Lilly’s ENLIGHTEN-6 obesity trial (six sites, 12,004 patients, 4.6M records, 63 criteria), Novartis’s PSMA-DC prostate cancer trial (5.2M records, six qualifying patients after two years of zero enrollment manually), and a UCB psoriatic arthritis trial (42 criteria, 650 patients, 14 qualifying patients in 11 days versus an estimated 195 hours manually).
Pros & Cons:
Pros: Connects directly to certified EHR systems rather than requiring manual record export, which removes the biggest operational bottleneck in trial pre-screening; returns evidence citations alongside candidate lists, so coordinators can verify why a patient matched instead of trusting an opaque score; handles scanned documents and faxed PDFs, which is where a large share of real-world clinical documentation lives; success-fee pricing with $0 upfront aligns cost with actual enrollment outcomes rather than seat or data volume; published case figures span multiple sponsors (Alnylam, Eli Lilly, Novartis, UCB) rather than a single anecdote; YC W25 backing and named EHR integrations suggest the compliance and connectivity work has been taken seriously.
Cons: **Extremely vertical**—it addresses clinical trial pre-screening only, so it is irrelevant to teams outside trial sites, CROs, and sponsors; **per-enrollment pricing is not disclosed**, and the publicly listed fees are waivers during a promotional window, so total cost still requires a sales conversation; **case figures are vendor-authored**—the Rundown AI notes that vendor case studies are not independent validation of sensitivity, specificity, fairness, or performance on new site populations; **independent user reviews are absent**—RightAIChoice scanned public community sources in August 2026 and could not confirm discussions referred to this HealthKey rather than same-named entities, so it declined to publish a sentiment score; **very early-stage**—roughly 10 employees, pre-seed funding (a Sydecar SPV sold about $484,833), so long-term scale is unproven; name collision with a UK health benefits platform (HealthKey by Vision RCL) creates search confusion.
Who is it for?:Clinical trial sites looking to reduce manual chart review for patient identification; CROs and sponsors that need faster, auditable pre-screening across multiple sites; research teams whose current process involves manually scanning EHR records against dozens of inclusion/exclusion criteria; organizations already on certified EHR systems that want integration without building custom data pipelines.